Newron Pharmaceuticals S.p.A. (SWX:NWRN)
Switzerland
· Delayed Price · Currency is CHF 6.31
+0.14 (2.27%)
Apr 10, 2025, 4:43 PM CET
Newron Pharmaceuticals Balance Sheet
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Cash & Equivalents | 6.93 | 6.34 | 13.42 | 25.02 | 13.21 | Upgrade
|
| Short-Term Investments | 2.89 | 6.26 | 9.35 | 9.58 | 18.04 | Upgrade
|
| Cash & Short-Term Investments | 9.83 | 12.6 | 22.77 | 34.59 | 31.25 | Upgrade
|
| Cash Growth | -22.01% | -44.68% | -34.17% | 10.70% | -20.21% | Upgrade
|
| Accounts Receivable | 42.12 | 2.02 | 1.94 | 1.31 | 6.62 | Upgrade
|
| Other Receivables | 4.94 | 3.16 | 3.03 | 2.74 | - | Upgrade
|
| Receivables | 47.06 | 5.18 | 4.97 | 4.05 | 6.62 | Upgrade
|
| Prepaid Expenses | 4.22 | 1.87 | 0.75 | 0.78 | - | Upgrade
|
| Total Current Assets | 61.1 | 19.65 | 28.49 | 39.43 | 37.87 | Upgrade
|
| Property, Plant & Equipment | 0.83 | 0.41 | 0.53 | 0.58 | 0.73 | Upgrade
|
| Other Intangible Assets | - | - | - | 0 | 0.01 | Upgrade
|
| Other Long-Term Assets | 1.97 | 5.81 | 8.18 | 10.48 | 12.58 | Upgrade
|
| Total Assets | 63.91 | 25.87 | 37.2 | 50.49 | 51.2 | Upgrade
|
| Accounts Payable | 2.47 | 2.02 | 1.91 | 1.5 | 1.27 | Upgrade
|
| Accrued Expenses | 4.94 | 3.49 | 2.17 | 1.1 | 3.28 | Upgrade
|
| Current Portion of Long-Term Debt | 13.41 | 22.28 | - | - | - | Upgrade
|
| Current Portion of Leases | 0.14 | 0.18 | 0.17 | 0.15 | 0.15 | Upgrade
|
| Other Current Liabilities | 2.55 | 0.97 | 0.79 | 0.9 | 2.19 | Upgrade
|
| Total Current Liabilities | 23.51 | 28.93 | 5.04 | 3.65 | 6.89 | Upgrade
|
| Long-Term Debt | 36.24 | 25.75 | 45.17 | 42.54 | 25.67 | Upgrade
|
| Long-Term Leases | 0.67 | 0.21 | 0.33 | 0.39 | 0.52 | Upgrade
|
| Other Long-Term Liabilities | 1.57 | 0.47 | 0.22 | 0.21 | 0.18 | Upgrade
|
| Total Liabilities | 62.45 | 55.77 | 51.23 | 47.38 | 33.95 | Upgrade
|
| Common Stock | 3.99 | 3.57 | 3.57 | 3.57 | 3.57 | Upgrade
|
| Additional Paid-In Capital | - | - | - | 5.1 | 26.1 | Upgrade
|
| Retained Earnings | 10.69 | -21.4 | -22.81 | -20.12 | -26.16 | Upgrade
|
| Comprehensive Income & Other | -13.22 | -12.08 | 5.21 | 14.55 | 13.74 | Upgrade
|
| Shareholders' Equity | 1.46 | -29.91 | -14.03 | 3.11 | 17.25 | Upgrade
|
| Total Liabilities & Equity | 63.91 | 25.87 | 37.2 | 50.49 | 51.2 | Upgrade
|
| Total Debt | 50.47 | 48.42 | 45.66 | 43.08 | 26.35 | Upgrade
|
| Net Cash (Debt) | -40.64 | -35.82 | -22.89 | -8.49 | 4.91 | Upgrade
|
| Net Cash Growth | - | - | - | - | -77.98% | Upgrade
|
| Net Cash Per Share | -1.98 | -2.01 | -1.28 | -0.48 | 0.27 | Upgrade
|
| Filing Date Shares Outstanding | 19.96 | 17.85 | 17.85 | 17.85 | 17.85 | Upgrade
|
| Total Common Shares Outstanding | 19.96 | 17.85 | 17.85 | 17.85 | 17.85 | Upgrade
|
| Working Capital | 37.6 | -9.27 | 23.45 | 35.77 | 30.98 | Upgrade
|
| Book Value Per Share | 0.07 | -1.68 | -0.79 | 0.17 | 0.97 | Upgrade
|
| Tangible Book Value | 1.46 | -29.91 | -14.03 | 3.11 | 17.24 | Upgrade
|
| Tangible Book Value Per Share | 0.07 | -1.68 | -0.79 | 0.17 | 0.97 | Upgrade
|
Updated Sep 19, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.